title: Salmon calcitonin and calcium in the treatment of male osteoporosis: the effect on bone mineral density.
abstract: OBJECTIVE
  To assess the effectiveness of salmon calcitonin in the therapy of male osteoporosis.
  
  
  METHODS
  Nine male patients aged 20-73 years with vertebral osteoporosis were included in this study. Patients were prescribed 100 units of salmon calcitonin injected subcutaneously three times per week over a period of three months, followed by three months without salmon calcitonin treatment. Thereafter the patients received another salmon calcitonin cycle for three months as described above. All men received calcium supplementation of 1000 mg/day throughout the study period of 12 months. Bone mineral density of the lumbar spine and at the hip was measured at the beginning and the end of the treatment period using DXA (n = 7) or QCT (n = 2).
  
  
  RESULTS
  Baseline evaluation revealed a bone mineral density of the lumbar spine of 0.78 +/- 0.09 g/cm2 and 0.62 +/- 0.09 g/cm2 at the hip. Treatment with salmon calcitonin resulted in a significant increase of vertebral bone mineral density to 0.80 +/- 0.09 g/cm2 (p < 0.015). Femoral bone mineral density also significantly increased after salmon calcitonin therapy to 0.64 +/- 0.11 g/cm2 (p < 0.05).
  
  
  CONCLUSIONS
  These results show that calcium and salmon calcitonin increase bone mineral density in male patients with osteoporosis. Calcium and calcitonin may be useful in the treatment of male osteoporosis; however, further studies are necessary before definite recommendations can be made.
authors.affiliation: Department of Internal Medicine III, University of Vienna, Austria.
authors.forename: L
authors.initials: L
authors.lastname: Erlacher
authors.forename: J
authors.initials: J
authors.lastname: Kettenbach
authors.forename: H
authors.initials: H
authors.lastname: Kiener
authors.forename: W
authors.initials: W
authors.lastname: Graninger
authors.forename: F
authors.initials: F
authors.lastname: Kainberger
authors.forename: P
authors.initials: P
authors.lastname: Pietschmann
mesh_terms: D000328:Adult; D000368:Aged; D000700:Analgesics / Q000008:administration & dosage*; D015519:Bone Density / Q000187:drug effects* / Q000502:physiology; D002116:Calcitonin / Q000008:administration & dosage*; D002118:Calcium / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D012189:Retrospective Studies
chemical_list: D000700:Analgesics; C028815:salmon calcitonin; D002116:Calcitonin; D002118:Calcium